Lv41
704 积分 2024-05-25 加入
Unravelling the GIPR agonist versus antagonist paradox
4小时前
已完结
The unexpected role of GIP in transforming obesity treatment
5小时前
已完结
Do weight loss interventions challenge the obesity paradox in heart failure?
5小时前
已完结
Targeting protein disorder: the next hurdle in drug discovery
1个月前
已完结
Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling
1个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
2个月前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
2个月前
已完结
Making good decisions in early drug discovery
3个月前
已完结
Fibrosis: cross-organ biology and pathways to development of innovative drugs
4个月前
已完结
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
4个月前
已完结
皖公网安备34019202002308
